Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1996 Jul;70(7):4253–4260. doi: 10.1128/jvi.70.7.4253-4260.1996

Immune evasion properties of herpes simplex virus type 1 glycoprotein gC.

H M Friedman 1, L Wang 1, N O Fishman 1, J D Lambris 1, R J Eisenberg 1, G H Cohen 1, J Lubinski 1
PMCID: PMC190356  PMID: 8676446

Abstract

Herpes simplex virus type I (HSV-1) glycoprotein gC binds complement component C3b, and purified gC inhibits complement activation. Two HSV strains carrying mutations in the gC gene which rendered them unable to bind C3b were compared with wild-type and marker-rescued viruses to evaluate the role of gC on the virion in protecting HSV-1 from complement-mediated neutralization. The gC mutant viruses were markedly susceptible to neutralization by nonimmune human serum, showing up to a 5,000-fold decline in titer after 1 h of incubation with serum. In contrast, wild-type or marker-rescued viruses showed a twofold reduction in titer. Studies with hypogammaglobulinemic and immunoglobulin G-depleted serum supported the observation that neutralization occurred in the absence of antibody. Neutralization of gC mutant strains by nonimmune serum was rapid; their half-life was 2 to 2.5 min, compared with 1 h for wild-type virus. Ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA)-treated human serum or C4-deficient guinea pig serum failed to neutralize gC mutant strains, indicating a role for components of the classical complement pathway. gC had little additional effect on neutralization by the combination of antibody plus complement compared with complement alone. The results indicate that the magnitude of the protection offered by gC-1 is larger than previously recognized; that in the absence of gC-1, complement neutralization is rapid and is mediated by components of the classical complement pathway; and that gC mainly protects against antibody-independent complement neutralization, suggesting a probable role for gC early in infection, before antibodies develop.

Full Text

The Full Text of this article is available as a PDF (333.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albrecht J. C., Fleckenstein B. New member of the multigene family of complement control proteins in herpesvirus saimiri. J Virol. 1992 Jun;66(6):3937–3940. doi: 10.1128/jvi.66.6.3937-3940.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alcamí A., Smith G. L. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell. 1992 Oct 2;71(1):153–167. doi: 10.1016/0092-8674(92)90274-g. [DOI] [PubMed] [Google Scholar]
  3. Baucke R. B., Spear P. G. Membrane proteins specified by herpes simplex viruses. V. Identification of an Fc-binding glycoprotein. J Virol. 1979 Dec;32(3):779–789. doi: 10.1128/jvi.32.3.779-789.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Daniels C. A., Borsos T., Rapp H. J., Snyderman R., Notkins A. L. Neutralization of sensitized virus by purified components of complement. Proc Natl Acad Sci U S A. 1970 Mar;65(3):528–535. doi: 10.1073/pnas.65.3.528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dubin G., Basu S., Mallory D. L., Basu M., Tal-Singer R., Friedman H. M. Characterization of domains of herpes simplex virus type 1 glycoprotein E involved in Fc binding activity for immunoglobulin G aggregates. J Virol. 1994 Apr;68(4):2478–2485. doi: 10.1128/jvi.68.4.2478-2485.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dubin G., Fishman N. O., Eisenberg R. J., Cohen G. H., Friedman H. M. The role of herpes simplex virus glycoproteins in immune evasion. Curr Top Microbiol Immunol. 1992;179:111–120. doi: 10.1007/978-3-642-77247-4_7. [DOI] [PubMed] [Google Scholar]
  7. Dubin G., Socolof E., Frank I., Friedman H. M. Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J Virol. 1991 Dec;65(12):7046–7050. doi: 10.1128/jvi.65.12.7046-7050.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ebenbichler C. F., Thielens N. M., Vornhagen R., Marschang P., Arlaud G. J., Dierich M. P. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med. 1991 Dec 1;174(6):1417–1424. doi: 10.1084/jem.174.6.1417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Edens R. E., Linhardt R. J., Bell C. S., Weiler J. M. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. Immunopharmacology. 1994 Mar-Apr;27(2):145–153. doi: 10.1016/0162-3109(94)90049-3. [DOI] [PubMed] [Google Scholar]
  10. Eisenberg R. J., Ponce de Leon M., Friedman H. M., Fries L. F., Frank M. M., Hastings J. C., Cohen G. H. Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2. Microb Pathog. 1987 Dec;3(6):423–435. doi: 10.1016/0882-4010(87)90012-x. [DOI] [PubMed] [Google Scholar]
  11. Frank I., Friedman H. M. A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. J Virol. 1989 Nov;63(11):4479–4488. doi: 10.1128/jvi.63.11.4479-4488.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Friedman H. M., Cohen G. H., Eisenberg R. J., Seidel C. A., Cines D. B. Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature. 1984 Jun 14;309(5969):633–635. doi: 10.1038/309633a0. [DOI] [PubMed] [Google Scholar]
  13. Friedman H. M., Yee A., Diggelmann H., Hastings J. C., Tal-Singer R., Seidel-Dugan C. A., Eisenberg R. J., Cohen G. H. Use of a glucocorticoid-inducible promoter for expression of herpes simplex virus type 1 glycoprotein gC1, a cytotoxic protein in mammalian cells. Mol Cell Biol. 1989 Jun;9(6):2303–2314. doi: 10.1128/mcb.9.6.2303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Früh K., Ahn K., Djaballah H., Sempé P., van Endert P. M., Tampé R., Peterson P. A., Yang Y. A viral inhibitor of peptide transporters for antigen presentation. Nature. 1995 Jun 1;375(6530):415–418. doi: 10.1038/375415a0. [DOI] [PubMed] [Google Scholar]
  15. Gerber S. I., Belval B. J., Herold B. C. Differences in the role of glycoprotein C of HSV-1 and HSV-2 in viral binding may contribute to serotype differences in cell tropism. Virology. 1995 Dec 1;214(1):29–39. doi: 10.1006/viro.1995.9957. [DOI] [PubMed] [Google Scholar]
  16. Gerhard W., Yewdell J., Frankel M. E., Webster R. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature. 1981 Apr 23;290(5808):713–717. doi: 10.1038/290713a0. [DOI] [PubMed] [Google Scholar]
  17. Goldstein D. J., Weller S. K. An ICP6::lacZ insertional mutagen is used to demonstrate that the UL52 gene of herpes simplex virus type 1 is required for virus growth and DNA synthesis. J Virol. 1988 Aug;62(8):2970–2977. doi: 10.1128/jvi.62.8.2970-2977.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gooding L. R. Virus proteins that counteract host immune defenses. Cell. 1992 Oct 2;71(1):5–7. doi: 10.1016/0092-8674(92)90259-f. [DOI] [PubMed] [Google Scholar]
  19. Gustafson K. S., Vercellotti G. M., Bendel C. M., Hostetter M. K. Molecular mimicry in Candida albicans. Role of an integrin analogue in adhesion of the yeast to human endothelium. J Clin Invest. 1991 Jun;87(6):1896–1902. doi: 10.1172/JCI115214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Harris S. L., Frank I., Yee A., Cohen G. H., Eisenberg R. J., Friedman H. M. Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralization. J Infect Dis. 1990 Aug;162(2):331–337. doi: 10.1093/infdis/162.2.331. [DOI] [PubMed] [Google Scholar]
  21. Hasty L. A., Lambris J. D., Lessey B. A., Pruksananonda K., Lyttle C. R. Hormonal regulation of complement components and receptors throughout the menstrual cycle. Am J Obstet Gynecol. 1994 Jan;170(1 Pt 1):168–175. doi: 10.1016/s0002-9378(94)70404-x. [DOI] [PubMed] [Google Scholar]
  22. Herold B. C., WuDunn D., Soltys N., Spear P. G. Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity. J Virol. 1991 Mar;65(3):1090–1098. doi: 10.1128/jvi.65.3.1090-1098.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hidaka Y., Sakai Y., Toh Y., Mori R. Glycoprotein C of herpes simplex virus type 1 is essential for the virus to evade antibody-independent complement-mediated virus inactivation and lysis of virus-infected cells. J Gen Virol. 1991 Apr;72(Pt 4):915–921. doi: 10.1099/0022-1317-72-4-915. [DOI] [PubMed] [Google Scholar]
  24. Hill A., Jugovic P., York I., Russ G., Bennink J., Yewdell J., Ploegh H., Johnson D. Herpes simplex virus turns off the TAP to evade host immunity. Nature. 1995 Jun 1;375(6530):411–415. doi: 10.1038/375411a0. [DOI] [PubMed] [Google Scholar]
  25. Hsu D. H., de Waal Malefyt R., Fiorentino D. F., Dang M. N., Vieira P., de Vries J., Spits H., Mosmann T. R., Moore K. W. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science. 1990 Nov 9;250(4982):830–832. doi: 10.1126/science.2173142. [DOI] [PubMed] [Google Scholar]
  26. Huemer H. P., Larcher C., van Drunen Littel-van den Hurk S., Babiuk L. A. Species selective interaction of Alphaherpesvirinae with the "unspecific" immune system of the host. Arch Virol. 1993;130(3-4):353–364. doi: 10.1007/BF01309666. [DOI] [PubMed] [Google Scholar]
  27. Hung S. L., Peng C., Kostavasili I., Friedman H. M., Lambris J. D., Eisenberg R. J., Cohen G. H. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway. Virology. 1994 Sep;203(2):299–312. doi: 10.1006/viro.1994.1488. [DOI] [PubMed] [Google Scholar]
  28. Hung S. L., Srinivasan S., Friedman H. M., Eisenberg R. J., Cohen G. H. Structural basis of C3b binding by glycoprotein C of herpes simplex virus. J Virol. 1992 Jul;66(7):4013–4027. doi: 10.1128/jvi.66.7.4013-4027.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Isaacs S. N., Kotwal G. J., Moss B. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):628–632. doi: 10.1073/pnas.89.2.628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Johnson D. C., Feenstra V. Identification of a novel herpes simplex virus type 1-induced glycoprotein which complexes with gE and binds immunoglobulin. J Virol. 1987 Jul;61(7):2208–2216. doi: 10.1128/jvi.61.7.2208-2216.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Johnson D. C., Frame M. C., Ligas M. W., Cross A. M., Stow N. D. Herpes simplex virus immunoglobulin G Fc receptor activity depends on a complex of two viral glycoproteins, gE and gI. J Virol. 1988 Apr;62(4):1347–1354. doi: 10.1128/jvi.62.4.1347-1354.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Kotwal G. J., Isaacs S. N., McKenzie R., Frank M. M., Moss B. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science. 1990 Nov 9;250(4982):827–830. doi: 10.1126/science.2237434. [DOI] [PubMed] [Google Scholar]
  33. Kubota Y., Gaither T. A., Cason J., O'Shea J. J., Lawley T. J. Characterization of the C3 receptor induced by herpes simplex virus type 1 infection of human epidermal, endothelial, and A431 cells. J Immunol. 1987 Feb 15;138(4):1137–1142. [PubMed] [Google Scholar]
  34. Litwin V., Sandor M., Grose C. Cell surface expression of the varicella-zoster virus glycoproteins and Fc receptor. Virology. 1990 Sep;178(1):263–272. doi: 10.1016/0042-6822(90)90402-d. [DOI] [PubMed] [Google Scholar]
  35. Marschang P., Sodroski J., Würzner R., Dierich M. P. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol. 1995 Jan;25(1):285–290. doi: 10.1002/eji.1830250147. [DOI] [PubMed] [Google Scholar]
  36. McNearney T. A., Odell C., Holers V. M., Spear P. G., Atkinson J. P. Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity. J Exp Med. 1987 Nov 1;166(5):1525–1535. doi: 10.1084/jem.166.5.1525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Moore K. W., Vieira P., Fiorentino D. F., Trounstine M. L., Khan T. A., Mosmann T. R. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science. 1990 Jun 8;248(4960):1230–1234. doi: 10.1126/science.2161559. [DOI] [PubMed] [Google Scholar]
  38. Nemerow G. R., Jensen F. C., Cooper N. R. Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement. J Clin Invest. 1982 Nov;70(5):1081–1091. doi: 10.1172/JCI110696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Ogata M., Shigeta S. Appearance of immunoglobulin G Fc receptor in cultured human cells infected with varicella-zoster virus. Infect Immun. 1979 Nov;26(2):770–774. doi: 10.1128/iai.26.2.770-774.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Ohmann H. B., Babiuk L. A. Induction of receptors for complement and immunoglobulins by herpesviruses of various species. Virus Res. 1988 Mar;9(4):335–342. doi: 10.1016/0168-1702(88)90092-5. [DOI] [PubMed] [Google Scholar]
  41. Phillips R. E., Rowland-Jones S., Nixon D. F., Gotch F. M., Edwards J. P., Ogunlesi A. O., Elvin J. G., Rothbard J. A., Bangham C. R., Rizza C. R. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature. 1991 Dec 12;354(6353):453–459. doi: 10.1038/354453a0. [DOI] [PubMed] [Google Scholar]
  42. Pircher H., Moskophidis D., Rohrer U., Bürki K., Hengartner H., Zinkernagel R. M. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature. 1990 Aug 16;346(6285):629–633. doi: 10.1038/346629a0. [DOI] [PubMed] [Google Scholar]
  43. Price J., Turner D., Cepko C. Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci U S A. 1987 Jan;84(1):156–160. doi: 10.1073/pnas.84.1.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Rother R. P., Rollins S. A., Fodor W. L., Albrecht J. C., Setter E., Fleckenstein B., Squinto S. P. Inhibition of complement-mediated cytolysis by the terminal complement inhibitor of herpesvirus saimiri. J Virol. 1994 Feb;68(2):730–737. doi: 10.1128/jvi.68.2.730-737.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Sissons J. G., Oldstone M. B., Schreiber R. D. Antibody-independent activation of the alternative complement pathway by measles virus-infected cells. Proc Natl Acad Sci U S A. 1980 Jan;77(1):559–562. doi: 10.1073/pnas.77.1.559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Smiley M. L., Friedman H. M. Binding of complement component C3b to glycoprotein C is modulated by sialic acid on herpes simplex virus type 1-infected cells. J Virol. 1985 Sep;55(3):857–861. doi: 10.1128/jvi.55.3.857-861.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Spriggs M. K., Hruby D. E., Maliszewski C. R., Pickup D. J., Sims J. E., Buller R. M., VanSlyke J. Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell. 1992 Oct 2;71(1):145–152. doi: 10.1016/0092-8674(92)90273-f. [DOI] [PubMed] [Google Scholar]
  48. Takeuchi Y., Porter C. D., Strahan K. M., Preece A. F., Gustafsson K., Cosset F. L., Weiss R. A., Collins M. K. Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature. 1996 Jan 4;379(6560):85–88. doi: 10.1038/379085a0. [DOI] [PubMed] [Google Scholar]
  49. Tal-Singer R., Peng C., Ponce De Leon M., Abrams W. R., Banfield B. W., Tufaro F., Cohen G. H., Eisenberg R. J. Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules. J Virol. 1995 Jul;69(7):4471–4483. doi: 10.1128/jvi.69.7.4471-4483.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Weiler J. M., Edens R. E., Linhardt R. J., Kapelanski D. P. Heparin and modified heparin inhibit complement activation in vivo. J Immunol. 1992 May 15;148(10):3210–3215. [PubMed] [Google Scholar]
  51. Welsh R. M. Host cell modification of lymphocytic choriomeningitis virus and Newcastle disease virus altering viral inactivation by human complement. J Immunol. 1977 Jan;118(1):348–354. [PubMed] [Google Scholar]
  52. Wirtz G. H., Price R. A., Mutchler B. A., Miller R. W. The first component of complement as a constituent of human salivary sediment. Arch Oral Biol. 1987;32(7):505–508. doi: 10.1016/s0003-9969(87)80012-2. [DOI] [PubMed] [Google Scholar]
  53. WuDunn D., Spear P. G. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J Virol. 1989 Jan;63(1):52–58. doi: 10.1128/jvi.63.1.52-58.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. York I. A., Roop C., Andrews D. W., Riddell S. R., Graham F. L., Johnson D. C. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell. 1994 May 20;77(4):525–535. doi: 10.1016/0092-8674(94)90215-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES